CCM
XERS icon

CTC Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

CTC Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,800
Closed -$30K – 161
2022
Q1 		$30K Buy
+11,800
New +$28.8K 0.08% 111

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CTC Capital Management's XERS Position: Q2 2022 in Review

CTC Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2022, closing a stake of 11,800 shares — an estimated $30K sold.

CTC Capital Management first reported a position in XERS in Q1 2022 and held it in 1 quarter. The position peaked at $30K in Q1 2022. 103 funds tracked by Wall St. Rank hold XERS as of Q2 2022.

  • CTC Capital Management reported no remaining Xeris Biopharma Holdings position as of Q2 2022 after selling out during the quarter.
  • CTC Capital Management sold 11,800 Xeris Biopharma Holdings shares in Q2 2022, an estimated $30K.
  • CTC Capital Management first reported a position in Xeris Biopharma Holdings in Q1 2022 and held it in 1 quarter.
  • CTC Capital Management's Xeris Biopharma Holdings position peaked at $30K in Q1 2022.
  • 103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2022.

Based on CTC Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.